{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-149776","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2021-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.277629+00:00","generated_at":"2026-06-28T00:48:29.765008+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Kiora Pharmaceuticals appoints David Hollander, MD, MBA to its Board of Directors","bullets":["Appointment effective December 13, 2021; press release issued December 15, 2021.","Hollander is Chief R&D Officer at Aerie Pharmaceuticals, with extensive ophthalmic industry experience.","He fills a vacancy created by board resignations in August 2021.","Will serve as Class III director until 2024 Annual Meeting of Stockholders.","Board determined he is independent under Nasdaq Capital Market rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-149776","json":"https://secwatch.observer/filing/0001104659-21-149776.json","markdown":"https://secwatch.observer/filing/0001104659-21-149776.md","text":"https://secwatch.observer/filing/0001104659-21-149776.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000110465921149776/0001104659-21-149776-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000110465921149776/tm2135455d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T00:48:29.765008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b72ad87864","claim":"David Hollander was appointed as Director at KIORA PHARMACEUTICALS INC.","evidence_excerpt":"On December 13, 2021, the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) appointed David Hollander, MD, MBA as a member of the Board to fill a vacancy created by the previously disclosed resignations of two directors from the Board in August 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000110465921149776/0001104659-21-149776-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}